Peroxisome proliferator-activated receptor-gamma agonists in the treatment of dermatoses

( views:390, downloads:0 )
Author:
LIN Xi-ran(First Affiliated Hospital of Dalian University, Dalian 116011, China)
HUANG Tian()
Journal Title:
INTERNATIONAL JOURNAL OF DERMATOLOGY AND VENEREOLOGY
Issue:
Volume 34, Issue 06, 2008
DOI:
Key Word:
Peroxisome proliferator-activated receptors;Skin diseases;Therapy

Abstract´╝Ü Recent data have shown that peroxisome proliferator-activated receptor (PPAR)-gamma regulates many biological processes in skin, including cell proliferation and differentiation, immune response and inflammatory reactions. Thus, it may serve as a novel target for the treatment of various skin disorders. Clinically, PPARgamma agonists have been used to treat psoriasis, psoriatic arthritis, atopic dermatitis, melanoma, hirsutism, vascular tumors and lipodystrophy. Investigations into PPAR agonists may develop new approaches to the treatment of skin disorders.

  • [1]Weindl G,Schafer-Korting M,Schaller M,et al.Peroxisome proliferator-activated receptors and their ligands:entry into the post-glucocorticoid era of skin treatment? Drugs.2005,65 (14):1919-1934.
  • [2]Stienstra R,Duval C,Muller M,et al.PPARs,Obesity,and Inflammation.PPAR Res,2007,2007:95974.
  • [3]Heikkinen S,Auwerx J,Argmann CA.PPARgamma in human and mouse physiology.Biochim Biophys Acta,2007,1771 (8):999-1013.
  • [4]Boyd AS.Thiazolidinediones in dermatology.Int J Dermatol,2007,46(6):557-563.
  • [5]Straus DS,Glass CK.Anti-inflammatory actions of PPAR ligands:new insights on cellular and molecular mechanisms.Trends Immunol,2007,28(12):551-558.
  • [6]Sun Y,Bennett A.Cannabinoids:A New Group of Agonists of PPARs.PPAR Res,2007,2007:23513.
  • [7]Michalik L,Wahli W.Peroxisome proliferator-activated receptors (PPARs) in skin health,repair and disease.Biochim Biophys Acta,2007,1771(8):991-998.
  • [8]Schmuth M,Jiang YJ,Dubrac S,et al.Thematic Review Series; Skin Lipids.Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology.J Lipid Res,2008,49(3):499-509.
  • [9]Szeles L,Torocsik D,Nagy L.PPARgamma in immunity and inflammation:cell types and diseases.Biochim Biophys Acta,2007,1771(8):1014-1030.
  • [10]Giaginis C,Margeli A,Theocharis S.Peroxisome proliferator-acfivated receptor-gamma ligands as investigational modulators of angiogenesis.Expert Opin investig Drugs,2007,16(10):1561.
  • [11]Bhagavathula N,Nerusu KC,Lal A,et al.Rosiglitazone inhibits proliferation,motility,and matrix metalloproteinase production in keratinocytes.J Invest Dermatol,2004,122(1):130-139.
  • [12]Dahten A,Mergemeier S,Worm M.PPARgamma expression profile and its cytokine driven regulation in atopic dermatitis.Allergy,2007,62(8):926-933.
  • [13]Varani J,Bhagavathula N,Ellis CN,et al.Thiazolidinediones:potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease.Expert Opin Investig Drugs,2006,15(11):1453-1468.
  • [14]Bongartz T,Coras B,Vogt T,et al.Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone:an open-label pilot study.Rheumatology (Oxford),2005,44(1):126-129.
  • [15]Behshad R,Cooper KD,Korman NJ.A retrospective case series review of the peroxisome proliferator-activated receptor ligand rnsiglitazone in the treatment of atopic dermatitis.Arch Dermatoi,2008,144(1):84-88.
  • [16]Bhagavathula N,Nerusu KC,Reddy M,et al.BP-1107[{2-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-ethyl}-methyl-amide]:a novel synthetic thiazolidinedione that inhibits epidermal hyperplasia in psoriatic skin-severe-combined immunodeficient mouse transplants after topical application.J Pharmacol Exp Ther,2005,315(3):996-1004.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn